2 July 2021 (Friday) - ASH Update

The nice people at the American Society of Hematology touched on a few items about haemostatsis in their most recent update. I’ve often mentioned that  struggle to find good CPD in that area…

Here are the highlights in clotting disorders:
Extended Thromboprophylaxis Does Not Reduce VTE Incidence in Hospitalized Patients With Cancer
Extended thromboprophylaxis with enoxaparin, betrixaban, or rivaroxaban does not reduce the risk of VTE events, but may increase the risk of bleeding, in these patients.
Edoxaban Likely Prevents VTE Recurrence in Patients With Lung Cancer, Despite High Rates of Bleeding
The use of edoxaban in patients with lung cancer helped prevent VTE recurrence over six months, but the therapy was associated with bleeding events and did not seem to improve survival substantially, according to research presented at the 2021 ASCO Annual Meeting.
Rivaroxaban Reduces Risk of Cardiovascular Events in Patients With Atrial Fibrillation on Hemodialysis
A low dose of rivaroxaban decreased fatal and nonfatal cardiovascular events and major bleeding complications in these patients, compared with vitamin K antagonists.

No comments:

Post a Comment